ISSN: 2755-9351

Journal of Alzheimer's Disease & Reports

SCIENTIFIC Research and Community

Research Article

Open Access

Beyond Antioxidant Neuroprotection: Palm-Derived Tocotrienols, Microglial Immunometabolism, and NLRP3 Inflammasome Signalling in Alzheimer's Disease—A Critical Review

Loso Judijanto

IPOSS Jakarta, Indonesia

ABSTRACT

Alzheimer's disease (AD) involves amyloid and tau pathology alongside dysregulated innate immunity, bioenergetic stress, and altered lipid processing. Palm-derived tocotrienols have been investigated for antioxidant and anti-inflammatory effects, yet it remains uncertain whether their actions extend to disease-relevant microglial immunometabolism and NLRP3 inflammasome signalling. This critical qualitative literature review interprets studies published principally during 2020–2026 across tocotrienol pharmacology, experimental neuroinflammation, AD microglial biology, inflammasome mechanisms, and translational research. Evidence indicates that microglial responses depend on disease stage, metabolic flexibility, APOE/TREM2-associated lipid handling, and selective inflammatory signaling. Tocotrienol-rich preparations reduce selected inflammatory readouts in non-AD experimental models; a structurally related vitamin E derivative suppresses NLRP3-associated pyroptosis in macrophages. These observations do not establish direct suppression of microglial NLRP3 by defined palm tocotrienol congeners in humans with AD. Divergent preparations, uncertain brain exposure, incomplete inflammasome assays, and limited clinical outcomes impede causal inference. The review proposes a congener-to-exposure-to-target-engagement framework that integrates compound identity, pharmacokinetics, inflammasome priming and activation, mitochondrial function, phagocytosis, and AD-specific biomarkers. Future investigations should prioritize patient-derived microglia, causal perturbation experiments, disease-stage stratification, and pharmacokinetic confirmation before clinical efficacy claims. The available evidence supports a mechanistically testable research program, not the clinical use of tocotrienols as an established Alzheimer's treatment.

***Corresponding author**

Loso Judijanto IPOSS Jakarta, Indonesia.

Received: October 24, 2026; **Accepted:** October 26, 2026; **Published:** October 31, 2026

Keywords: Alzheimer's Disease, Palm-Derived Tocotrienols, γ-Tocotrienol, δ-Tocotrienol, Microglia, Immunometabolism, NLRP3 Inflammasome, Mitophagy, Neuroinflammation, Translational Neuroscience

JEL Classification: I10; I12; I19; O32; Q16.

Introduction

Background and Research Problem

Alzheimer's disease (AD) presents an intertwined biological challenge rather than a disorder reducible to a single misfolded protein or oxidative mechanism. Amyloid-β aggregates and pathological tau remain central to biological diagnosis and therapeutic development, but progressive synaptic dysfunction also reflects interactions among cellular stress responses, the cerebral vasculature, innate immunity, and systemic metabolic disturbances. Microglia are especially relevant because they surveil neural tissue, respond to damaged structures, shape amyloid plaque architecture, remove cellular debris, and influence neighboring neurons and astrocytes. These functions can promote resilience in one setting while contributing to pathology in another. A modern account of AD must therefore explain the timing, context, and consequences of microglial responses rather than labeling microglial activation as intrinsically harmful [1-5].

Natural vitamin E-related compounds have attracted attention as candidate neuroprotective agents partly because lipid oxidation and redox-sensitive signalling occur during neurodegeneration. Palm oil is a commercially important source of tocotrienols, members of the vitamin E family whose unsaturated isoprenoid side chains distinguish them from tocopherols. Tocotrienols can interact with cellular membranes and molecular regulatory pathways, making an exclusively free-radical-scavenging explanation insufficient to characterize their possible effects. Nevertheless, the presence of an attractive molecular mechanism does not imply that a compound reaches the human brain at pharmacologically meaningful concentrations. The scientific question is whether properly characterized palm-derived congeners modify pathways that matter for AD progression under realistic exposure conditions [6-10].

A particularly compelling convergence concerns NLRP3 inflammasome biology and microglial metabolism. The NLRP3 multiprotein complex participates in innate danger sensing and can contribute to caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin-D-dependent pyroptosis. In experimental AD systems, NLRP3 is also linked to glutamine utilization, mitochondrial function, and altered phagocytosis. Consequently, inflammasome signalling may influence disease through processes

wider than inflammatory cytokine production alone. The challenge is to determine which immunometabolic relationships are causally established in AD models and whether tocotrienol-specific evidence intersects with those relationships [11-15].

Urgency and Novelty

The urgency of this review follows from two simultaneous research developments. One is the growing sophistication of experimental studies that identify heterogeneous, genotype-dependent microglial states, including lipid-droplet-accumulating cells and distinct metabolic programs. The other is the expansion of pharmacological and nutritional investigations of tocotrienol-rich fractions that frequently report reductions in oxidative stress or broad inflammatory markers. These literatures often develop separately, and the terminology used in one field does not always correspond to the validated molecular measurements required in the other. Integrating them creates an opportunity to refine therapeutic hypotheses while preventing premature clinical interpretation

.

Recent tocotrienol investigations illustrate both the opportunity and the boundary of current knowledge. Experimental work has shown changes in microglial activation or inflammatory gene expression after administration of tocotrienol preparations, and laboratory work on garcinoic acid has shown reduced NLRP3-related responses in murine macrophages. These studies are important but address different compounds, model systems, and outcomes. Garcinoic acid in those experiments was obtained from Garcinia kola, not demonstrated to be a palm-extracted drug, while macrophage findings cannot automatically be transferred to human microglia exposed to AD pathology. The originality of the present article therefore lies in critically distinguishing these inferential steps within a qualitative, mechanism-based synthesis [16-20].

Purpose, Questions and Scholarly Contribution

The review asks to what extent evidence supports the hypothesis that palm-derived tocotrienols could modify AD-relevant microglial immunometabolism and NLRP3 signalling. It examines how congener identity affects pharmacological interpretation; how glycolysis, mitochondrial activity and lipid handling organize microglial function; which NLRP3 endpoints establish target engagement; and which translational barriers currently prevent claims of patient benefit. The intended contribution is not a recommendation for supplementation or a pooled treatment effect. Rather, it is an explanatory model connecting chemical identity to delivered dose, molecular effects, protective immune functions, and clinically meaningful disease outcomes, with uncertainty made explicit at each link [21-25].

Literature Review

Tocotrienol Identity, Source and Biological Specificity

Vitamin E encompasses tocopherols and tocotrienols, each with alpha, beta, gamma and delta congeners distinguished by substitution of the chromanol ring. Tocotrienols have an unsaturated side chain that affects membrane interaction and biological distribution, but the resulting pharmacological profile cannot be assumed to be identical across congeners. Commercial palm tocotrienol-rich fractions can also contain tocopherols and other minor components, with relative proportions varying by raw material and processing method. Unless preparations are analytically standardized, a result attributed to 'tocotrienols' may reflect a mixture, an interaction among congeners, or unidentified co-constituents. Formulation identity is therefore not a peripheral manufacturing issue but a primary determinant of causal interpretation .

The distinction between parent compounds and their metabolites also matters. Vitamin E metabolites may influence inflammatory enzymes, transcriptional regulators, and lipid-mediator pathways, sometimes through mechanisms not reducible to direct ROS scavenging. Garcinoic acid is a carboxylated tocotrienol-related structure studied in inflammatory models, but it should not be presented as interchangeable with pure palm-derived δ-tocotrienol. Recent work on tocotrienol metabolites suggests potential shifting of innate immune lipid mediators toward resolution-associated patterns. Although provocative, demonstrations in peripheral immune cells or acute inflammatory systems remain insufficient to infer brain exposure or therapeutic benefit in AD

AD Neuroinflammation Beyond the Binary Activation Model

Microglia are adaptive neural-resident immune cells whose responses depend on cell state, regional environment, age, amyloid burden, tau pathology and genetic context. Their actions include phagocytosis, extracellular matrix remodeling, synaptic interactions, inflammatory signalling and maintenance of lipid balance. Interventions that reduce expression of a broad activation marker could impair beneficial plaque containment or clearance while appearing anti-inflammatory. Thus, a mechanistically credible review must separate adaptive activation, persistent dysfunction, immunological resolution and loss of cellular capacity. Work in human models and in mouse amyloidosis shows that the same cell population can perform protective and detrimental functions at different disease stages [26-30].

Single-cell and experimental investigations reveal a degree of complexity that the classic M1/M2 polarization framework fails to capture. Microglia may display disease-associated, senescent-like, lipid-laden, interferon-responsive, proliferative, or other transcriptional signatures, with state boundaries shaped by analytical method and biological context. TREM2-associated activation is not uniformly beneficial: certain models link its activity to plaque engagement, whereas others identify senescence-like states among TREM2-expressing microglia. Accordingly, a compound that decreases one inflammatory transcript without improving metabolism or phagocytosis cannot be said to 'normalize microglia.' The desired endpoint is the restoration of functional competence in a defined biological context

Human-cell atlases sharpen the distinction between descriptive activation signatures and functions that may be modified safely. An integrated Human Microglia Atlas spanning neurological conditions identified multiple microglial populations, including lipid-associated activated states, rather than a uniform activated phenotype. More recently, spatial and single-nucleus analyses of aged human brain tissue identified an amyloid-to-tau transition accompanied by shifts in microglial programs; resilient individuals showed different relationships among microglial signatures, tau accumulation and cognitive status. These findings caution that a reduction in one cytokine or transcriptional marker cannot be translated into a universal claim of beneficial microglial reprogramming. Congener-specific tocotrienol hypotheses should therefore specify the microglial state, neuropathological context and functional outcome before asserting mechanistic relevance.

Immunometabolic Flexibility

Microglial immunometabolism refers to reciprocal regulation between cellular bioenergetics and immune functions. Oxidative phosphorylation and mitochondrial substrate oxidation can support

surveillance, processing of engulfed material and biosynthetic demands, while enhanced glycolysis can help meet rapid activation requirements. Neither pathway is intrinsically healthy or diseased; what matters is whether metabolic responses remain proportionate to the duration and nature of the stimulus. Chronic amyloid- and tau-related stress may create a mismatch between inflammatory activity and the energy available for lysosomal digestion, membrane remodeling and synaptic maintenance. Reviews of AD microglia increasingly interpret such failures in terms of stage-specific metabolic adaptation and decompensation.

Glutamine metabolism provides a striking example of reciprocal control. In AD models, altered glutamine utilization has been implicated in NLRP3 activity and microglial phagocytosis, while AMPK, mTORC1 and mitophagy link nutrient sensing to mitochondrial quality. In one experimental program, interfering with glutaminase-associated pathways influenced mitophagy and inflammasome activity; in another, NLRP3 manipulation altered glutamine-related metabolism and clearance of amyloid. These relationships do not imply a single linear pathway because the direction of causality depends on model conditions and the chosen intervention. They do show why measuring only ROS or TNF-α is inadequate to establish an immunometabolic mechanism for a proposed bioactive agent.

Lipid Handling, APOE and TREM2

Lipid metabolism is inseparable from microglial function because cells must acquire, transport, store and oxidize lipids arising from membranes and engulfed material. TREM2 influences responses to lipid-rich material and has been shown to regulate microglial cholesterol-associated programs under chronic phagocytic challenge. APOE genotype adds another layer of complexity, particularly in AD. Microglia exposed to amyloid can accumulate lipid droplets, and studies of APOE4/4 microglia link a lipid-droplet-associated state to altered phagocytosis, inflammatory secretion and neurotoxic signalling. Yet lipid droplets can also buffer potentially harmful free fatty acids; their mere presence should not be treated as equivalent to pathogenic dysfunction.

Recent investigations link lipid storage to specific molecular machinery, including DGAT2-mediated triglyceride formation and impaired lipid-droplet processing. In human-mouse chimeric and cellular models, plaque-associated microglia accumulate lipids, while intervention on lipid-processing pathways can modify amyloid uptake and neuronal injury. These findings sharpen the relevance of tocotrienol research to cellular lipid environments, but they do not show that oral tocotrienols correct APOE-dependent lipid abnormalities. A plausible target pathway and a demonstrated drug effect remain different categories of evidence. Compound-specific studies should measure lipid composition, lipophagy, organelle stress and cell function rather than treating total lipid accumulation as a sufficient outcome.

NLRP3 Priming, Activation and Downstream Pathways

Canonical NLRP3 signalling is often described as a two-stage process. Priming through pattern-recognition or cytokine pathways can increase NLRP3 and pro-IL-1β expression, frequently involving NF-κB, while a second set of cellular disturbances facilitates inflammasome assembly and activation of caspase-1. The resulting cleavage of IL-1β and IL-18 and processing of gasdermin D can lead to inflammatory mediator release and pyroptotic membrane damage. However, an observed decrease in NF-κB-regulated transcripts addresses priming, not necessarily assembly or enzymatic activity of the inflammasome. Rigorous inference requires complementary assays that discriminate these levels.

The relevance of NLRP3 to AD extends to interactions with amyloid, tau, protein clearance, mitochondrial stress and immune-cell viability. Experiments have examined suppression of inflammasome signalling through genetic deletion, selective pharmacological inhibition, and changes in autophagy-dependent turnover of NLRP3. Tau-related experiments additionally suggest direct or indirect feedback between tau pathology and inflammasome activation. Nevertheless, the therapeutic interpretation is complicated because changing inflammasome activity may also reprogram glutamine metabolism and phagocytosis independently of classical cytokine readouts. A convincing tocotrienol study would need to show whether it acts on priming, activation, metabolic feedback or several pathways in parallel

Redox and Transcriptional Pathways

Oxidative stress participates in inflammatory signalling, protein damage and mitochondrial dysfunction, yet 'antioxidant activity' is not a singular biological endpoint. Nrf2-associated transcription can influence cellular stress responses, whereas NF-κB affects inflammatory gene regulation and may be shaped by feedback from ROS, cellular metabolites and cytokines. An intervention that alters a redox assay may affect gene expression without inhibiting the inflammasome complex itself. Tocotrienol-associated modulation of NF-κB has been discussed across experimental systems, but the extent to which particular congeners directly engage AD-relevant microglial targets remains unresolved. Mechanistic claims must be tested with pathway-specific perturbations rather than inferred from correlations.

Clinical Context and Endpoints

Clinical AD treatment increasingly incorporates pathological confirmation and stratification by amyloid and tau biomarkers. Anti-amyloid antibodies have shown measurable slowing of disease progression in selected early AD trial populations, but they do not establish that unrelated anti-inflammatory or nutritional agents will produce similar outcomes. Biomarker-based diagnosis is becoming more feasible with validated blood assays, although biomarkers of general glial activation remain less specific than core amyloid and tau markers. Translational tocotrienol studies would need outcomes that bridge target engagement and clinical function rather than relying solely on peripheral inflammatory proteins.

Methodology

Research Design and Epistemological Position

This article applies a critical qualitative literature review (QLR) methodology aimed at explaining mechanisms, interpreting contradictions and constructing a testable conceptual framework. It is not a systematic literature review, does not claim exhaustive retrieval, and does not estimate pooled treatment effects. The approach is appropriate because the evidence spans different fields and model classes: clinical AD research, experimental microglial immunology, lipid biochemistry, tocotrienol pharmacology and pharmaceutical delivery. A purely numerical synthesis could conceal the fundamental non-equivalence of exposures, disease models and outcome measures. The organizing purpose is therefore interpretive integration rather than enumeration of studies.

Identification and Selection of Literature

The search-oriented scoping strategy emphasized peer-reviewed journal publications issued from January 2020 through October

2026, with priority given to PubMed-indexed experimental studies, clinical trials and authoritative reviews. Search concepts were combined iteratively, including 'tocotrienol' OR 'tocotrienol-rich fraction' OR 'garcinoic acid' with 'microglia,' 'neuroinflammation,' 'NLRP3,' 'inflammasome,' 'NF-κB,' 'Alzheimer,' 'immunometabolism,' 'mitophagy,' 'APOE,' 'TREM2' and 'bioavailability.' Sources were retained when they clarified a central pathway, challenged an emerging interpretation, described an appropriate experimental model, or informed the clinical translation of the hypothesis. Search coverage was purposive, not exhaustive.

Source Appraisal and Thematic Analysis

The appraisal prioritized experimental appropriateness, compound characterization, evidence of causal manipulation, relevance of the AD model, measurement validity and translational proximity. Primary studies were considered more persuasive for specific effects than secondary summaries; reviews were used to establish conceptual context and identify unresolved issues. Human data were not automatically assigned superior mechanistic specificity, because uncontrolled observational associations may be less informative about mechanisms than well-controlled perturbation experiments. Conversely, preclinical findings were not treated as evidence of clinical efficacy. The analysis grouped findings into compound chemistry, microglial metabolic states, NLRP3 signalling, tocotrienol-specific experiments, pharmacokinetics, and clinical translation.

Evidence Categories and Inferential Boundaries

Four categories guided interpretation: direct AD-specific findings involving defined tocotrienols, non-AD tocotrienol findings involving relevant cell or molecular mechanisms, AD-specific findings involving other interventions, and broader theoretical or pharmacological evidence. Direct AD-specific evidence would be required to support a compound–disease mechanism; evidence from macrophages or inflammatory mice could support plausibility but not establish the same effect in AD microglia. For example, garcinoic-acid inhibition of macrophage NLRP3 cannot by itself demonstrate target engagement by palm tocotrienols in a patient's brain. This distinction was maintained throughout all thematic conclusions and the proposed research agenda.

Analysis of Contradictory Findings and Limitations

Apparent contradictions were interpreted as potentially arising from different congeners, mixed formulations, administration methods, experimental timing, cell sources, genotypes and endpoints. Special weight was given to negative or neutral human evidence, because confirmation bias can otherwise transform a review of plausible mechanisms into unwarranted therapeutic advocacy. The 2026 CADASIL trial was included as a translational caution, not as direct evidence of failure in AD. Since QLR selection is interpretive, undiscovered studies and unmeasured selection effects remain limitations; the manuscript therefore presents a bounded conceptual synthesis rather than a numerical measure of certainty.

Results: Thematic Findings

Theme I: Chemical Heterogeneity Produces Heterogeneous Biological Meaning

The first thematic finding is that the phrase 'palm tocotrienols' often refers to a family of chemically related but pharmacologically non-identical exposures. Studies employ mixtures, purified congeners, different carriers, varying tocopherol content, or structurally related metabolites. Reported anti-inflammatory effects consequently cannot be pooled conceptually without first identifying the exact tested material. Palm-source traceability is also essential when authors discuss metabolites from other plants. The evidence most directly relevant to NLRP3 includes carboxylated derivatives such as garcinoic acid, but these derivative studies should be interpreted as structural analog evidence rather than direct testing of dietary palm tocotrienols.

Bioavailability is a related and often underestimated determinant. Human pharmacokinetic studies of tocotrienols indicate substantial variation in systemic exposure among formulations, while self-emulsifying technologies and nanoencapsulation can alter absorption or tissue distribution. Importantly, elevated plasma concentration does not guarantee sufficient brain delivery, and brain-tissue measurements from experimental animals are not automatically transferable to humans. An experimentally active in vitro dose may exceed free concentrations realistically achievable within human microglia. Thus, negative experiments at inadequate exposure and positive experiments at physiologically implausible concentrations can both mislead interpretation if concentrations are not carefully contextualized.

Theme II: Microglia Undergo Stage-Dependent Functional Reorganization

The second thematic finding is that microglia cannot be divided cleanly into beneficial resting and harmful activated categories. Studies of plaque biology indicate that microglia may contribute to early plaque seeding under some conditions while subsequently compacting established deposits and limiting local neuritic damage. TREM2 expression can accompany phagocytosis-associated programs but also certain senescence-like signatures, indicating that one receptor or transcriptional marker cannot summarize the overall cell state. Therapeutic hypotheses that propose generalized 'deactivation' risk overlooking the possibility of harming plaque containment or tissue repair. Functional outcomes should include uptake, lysosomal degradation, plaque interaction and synaptic consequences.

A further finding within this theme is the importance of genetic and metabolic heterogeneity. APOE4-associated glial cells show altered lipid storage and functional responses, while experiments manipulating microglial insulin signalling or TREM2 reveal links between metabolism and amyloid uptake. Recent human-cell work on microglial cross-talk further suggests that interactions with neurons, other glia and extracellular signals are not merely background conditions. The effects of tocotrienols may differ across these cellular phenotypes, but direct congener-by-genotype experiments remain scarce. Consequently, average inflammatory readouts across an unstratified cell population may obscure opposite responses in distinct microglial states.

Theme III: NLRP3 and Metabolism form Reciprocal Rather than One-Way Pathways

The third thematic finding challenges the idea that NLRP3 is only a terminal cytokine-production switch. Experimental AD studies connect NLRP3 to glutaminolysis, mitochondrial activity, epigenetic regulation and phagocytosis. Zhang and colleagues linked metabolic regulation and mitophagy with NLRP3 activity, whereas McManus and colleagues reported that NLRP3 manipulation can alter glutamine-related programs that influence amyloid clearance. These findings support reciprocal immunometabolic relationships but should not be collapsed into one universal diagram applicable to all microglia. Mechanistic evaluation of candidate compounds therefore requires paired immune and metabolic readouts measured in the same experimental system

Human therapeutic tissue studies offer an independent test of what useful microglial activity can involve. Spatial transcriptomic analysis of brain tissue from people exposed to active or passive amyloid immunisation identified microglial states associated with amyloid removal, with TREM2-, APOE- and complement-related programs varying by anatomical context. The observed association does not establish that any tocotrienol preparation can reproduce these programs, but it establishes a clinically grounded reason to assess beneficial clearance functions alongside suppression of inflammatory signals. In particular, simultaneous evaluation of amyloid uptake, lysosomal degradation, regional context and cell survival is more informative than the change in a single cytokine readout.

Autophagic and lysosomal processes appear particularly important to this reciprocity. Studies involving p62-dependent NLRP3 degradation, mitophagy-linked signalling and exposure-related impairment of microglial autophagic flux indicate that inflammasome abundance, mitochondrial quality and intracellular waste handling can be mutually reinforcing. Nevertheless, detecting LC3 accumulation does not necessarily prove enhanced autophagic flux, just as reduced total NLRP3 protein does not necessarily demonstrate decreased assembly of the activated complex. Interpretation requires dynamic autophagy assays and inflammasome readouts beyond transcript abundance. These distinctions are critical in natural-product studies that rely on a limited panel of molecular markers.

Theme IV: Palm Tocotrienol Experiments Show Signals, but not Complete Pathway Proof

The fourth finding concerns the direct tocotrienol literature. Okuyama and colleagues observed attenuation of microglial activation and selected neuroinflammatory effects in an LPS-challenged mouse model receiving tocotrienols, suggesting biological activity in an inflammatory brain context. Such an LPS model is valuable for investigating innate immune responses, but it does not reproduce the progressive combination of amyloid, tau, aging and cell-state heterogeneity observed in AD. In the study, not all inflammatory markers responded significantly, underscoring the danger of translating a favorable subset of measurements into a broad mechanistic claim. The result supports further exploration rather than evidence of Alzheimer's disease modification.

A 2026 investigation of tocotrienol-rich fraction reported reduced nitric oxide and ROS in BV2 microglial cells and changes in selected inflammatory and neuronal-signalling transcripts in an experimental rat paradigm. The work advances the evidence beyond chemical antioxidant assays, yet it does not establish NLRP3 assembly, caspase-1 cleavage, ASC speck formation or gasdermin-D-mediated pyroptosis as causal mechanisms. It also uses a mixed preparation, which limits attribution to γ- or δ-tocotrienol. Taken together with cellular studies of BDNF-related activity, these findings suggest multiple candidate pathways but do not determine which mechanism is decisive for any observed behavioral effect.

Garcinoic acid provides the clearest biochemical bridge to inflammasome-associated outcomes, though it also illustrates why source and model distinctions matter. Börmel and colleagues examined a vitamin E derivative isolated from Garcinia kola and reported reduced NF-κB responses, caspase-1 processing and pyroptosis in stimulated murine macrophages. The study included comparison with a recognized NLRP3 inhibitor, making it more informative than experiments reporting cytokine changes alone. Nevertheless, the evidence concerns a derivative, macrophages and an induced inflammatory system rather than defined palm-derived congeners in AD microglia. Whether δ-tocotrienol generates sufficient amounts of analogous metabolites in human brain tissue remains an open question.

4.5. Theme V: Direct AD experiments in other compounds inform design, not efficacy

The fifth theme concerns insights from studies targeting NLRP3 or related neuroimmune mechanisms with agents other than tocotrienols. Investigations using inflammasome inhibitors, interleukin-1 pathway modulation, and natural compounds that influence mitophagy provide evidence that these mechanisms can be experimentally manipulated. Such studies help identify assays, positive controls and intervention timing for future tocotrienol work. They cannot be treated as evidence that tocotrienols will achieve the same molecular effect or therapeutic response. The distinction is especially important when the proposed compound differs in potency, brain exposure, receptor binding and metabolic conversion.

Mechanistic specificity may be even more challenging than showing a favorable phenotype. A substance can decrease IL-1β secretion by limiting cell viability, reducing transcriptional priming, suppressing mitochondrial stress, interfering with caspase-1 activity, or altering secretion pathways. These mechanisms have different implications for immune competence and safety. Studies that incorporate genetic knockout, selective inhibition, rescue experiments and paired functional endpoints are more persuasive than descriptive reductions in cytokines. Future palm tocotrienol experiments should therefore build on the methodological strengths of established NLRP3 research without importing conclusions that the compounds themselves have not earned

Theme VI: Clinical Translation Remains Unproven

The final thematic finding is the substantial gap between laboratory neuroimmune effects and human cognitive outcomes. Reviews of palm tocotrienol-rich fraction trials encompass varied indications and formulations, limiting application to disease-specific neurodegeneration. A randomized 2026 study in CADASIL did not show a reduction in its composite clinical progression endpoint after two years of a tocotrienol-rich preparation. Although CADASIL is a different disorder, the neutral outcome challenges the general expectation that plausible neuroprotective mechanisms reliably produce measurable clinical benefit in chronic brain disease. Such trials cannot be dismissed simply because they conflict with favorable laboratory results.

For AD, future studies would need to distinguish biological target engagement, disease biomarkers and functional outcomes. Plasma GFAP, neurofilament light, tau biomarkers and inflammatory imaging can contribute different information, but no single surrogate can establish that a tocotrienol preparation improves memory or alters disease trajectory. Blood-based biomarker recommendations emphasize analytic validity and clinical context, while TSPO PET research highlights limitations in equating imaging signals with a specific beneficial or harmful microglial state. Where clinical studies are eventually justified, cognition, daily function, adverse effects and objective drug exposure must remain integral endpoints.

Figure 1 presents the combined evidence architecture emerging from the six themes, highlighting why each transition from tocotrienol chemistry to Alzheimer's outcomes must be evaluated independently. This evidence-gated summary also anticipates the

causal limitations addressed in the Discussion.




Figure 1: Evidence-Gated Chain from Chemical Identity to Patient-Relevant Outcomes.

Figure 1 integrates the six thematic findings into a causal chain that deliberately inserts exposure and validation checkpoints between the oral preparation and any proposed clinical consequence. The diagram separates compound identity, bioavailability, microglial target engagement, pathway modulation and patient outcomes so that a positive finding in one domain is not silently promoted into proof at the next. This distinction is especially necessary for NLRP3, where priming, assembly and downstream pyroptosis have different biomarkers and do not necessarily move together.

Discussion and Analysis

Reconsidering Antioxidant Neuroprotection

The cumulative evidence supports moving beyond a narrow antioxidant paradigm, but not abandoning redox biology. Oxidation and membrane peroxidation interact with inflammatory transcription, mitochondrial function and cell fate; the conceptual mistake is to treat all reductions in ROS as interchangeable with disease modification. Tocotrienols may modify more than one biological process, yet the exact balance of direct scavenging, altered signalling, metabolite actions and systemic effects remains unclear. By situating compound chemistry within immunometabolic networks, the review transforms 'antioxidant potential' from a broad promotional description into a series of testable molecular propositions. Each proposed mechanism requires its own dose, time, tissue and outcome conditions.

One proposition is that certain congeners or metabolites could influence inflammatory priming through NF-κB-associated pathways. A separate proposition is that they might alter mitochondrial stress sufficiently to reduce the second activation step of the NLRP3 inflammasome. A third concerns the possibility of facilitating resolution-associated lipid-mediator patterns without abolishing phagocytosis or tissue-repair functions. These pathways are related but not equivalent, and evidence for one cannot substitute for direct evidence of another. The emerging metabolite literature is therefore intellectually valuable precisely because it expands the set of experiments that should be performed, not because it establishes a ready-made AD therapy.

Precision Immunometabolic Targeting Rather than Indiscriminate Suppression

A more defensible therapeutic aspiration is precision immunometabolic modulation: preserving microglial energy competence and adaptive surveillance while limiting persistently harmful inflammatory responses. This is different from global immunosuppression, and it creates a practical requirement to track both improvements and unintended impairment. For instance, decreased cytokine secretion would be insufficient if accompanied by weakened amyloid uptake, reduced plaque compaction or failure to process engulfed material. An ideal experiment should establish that suppression of maladaptive signalling occurs concurrently with preservation or recovery of selected protective functions. This dual-outcome standard is more demanding than traditional natural-product neuroprotection assays but better aligned with AD biology.

Disease stage should be treated as a primary modifier rather than an afterthought. Early microglial metabolic adaptation may support responses to emerging pathology; later chronic inflammation and lipid overload can coexist with declining functional capacity. Interventions could therefore have different consequences before plaque formation, during plaque containment, and after significant tau-associated neuronal injury. The concept of a uniform anti-inflammatory benefit across stages is difficult to reconcile with current experimental evidence. Longitudinal study designs should include early and late treatment arms, appropriate disease-stage biomarkers, and cell-state analyses performed before and after exposure.

The human pathological continuum provides a further reason not to treat all inflammatory states as equivalent treatment targets. Lu observed state transitions around an amyloid–tau inflection point and different microglial patterns in cognitively resilient individuals, indicating that pathology, response and outcome need not move in lockstep. Accordingly, experimental intervention windows should be defined by biological disease markers and microglial functional measurements, not by chronological age or generic exposure to amyloid alone. This approach could also help explain why an intervention considered anti-inflammatory in an early adaptive state may have different effects when clearance capacity is already compromised.

APOE and TREM2 variation further strengthen the case for stratification. APOE4 can be linked to lipid droplet-associated microglial dysfunction, while alterations in TREM2-related signalling may change cholesterol handling, metabolic capacity and responsiveness to receptor-targeted therapies. These pathways create biologically plausible settings in which a lipid-soluble natural compound might have genotype-specific effects. Yet the present literature provides no basis for claiming superior tocotrienol response in APOE4 carriers or any particular TREM2 genotype. Such claims should await experiments with isogenic human cell lines, independent donor backgrounds and careful replication

The NLRP3 Hypothesis Requires Target Validation

The key original thesis is a conditional one: if defined palm-derived tocotrienol congeners reach AD-relevant microglia at sufficient concentrations, and if they selectively alter NLRP3-associated immunometabolic dysfunction without undermining protective activity, then they could justify more advanced investigation. None of these conditions can be bypassed by presenting an inflammatory biomarker reduction as proof. Demonstrating lower NLRP3 messenger RNA addresses expression, not assembly; demonstrating lower IL-1β release may reflect several upstream or downstream changes; and demonstrating reduced ROS does not establish caspase-1 inhibition. The field requires direct target-validation experiments and biologically realistic exposure controls.

A suitable molecular panel would include measures of priming, such as RELA translocation and pro-IL-1β expression; activation, such as ASC specks, cleaved caspase-1 and mature IL-1β/IL-18; and cell fate, such as gasdermin-D cleavage and pyroptotic membrane permeability. These assays should be paired with mitochondrial respiration, glycolytic capacity, ROS and mitochondrial-membrane measures, as well as lysosomal acidification, autophagic flux and phagocytosis. Genetic deletion or rescue of NLRP3, upstream pathway inhibitors and orthogonal assays would help distinguish direct and indirect effects. Establishing a pattern across these endpoints would provide stronger evidence than focusing on a single statistically significant marker.

As shown in Figure 2, the proposed NLRP3 hypothesis must be tested across priming, complex activation, downstream immune products, and metabolic feedback rather than through a single inflammatory marker. The dashed intervention routes represent propositions for investigation, not confirmed effects of palm tocotrienols in human Alzheimer's disease.




Figure 2: NLRP3 Priming, Activation, Downstream Responses and Immunometabolic Feedback.

Figure 2 shows an experimentally useful division between inflammasome priming, inflammasome assembly and cellular outcomes. The dashed points of possible tocotrienol action are explicitly hypotheses rather than established causal relationships in Alzheimer's disease. The diagram also emphasizes reciprocal metabolic feedback, because alterations in glutamine utilization, mitochondrial quality and lysosomal activity may change inflammatory readouts even when a compound does not interact directly with the NLRP3 protein complex.

Reconciling Competing Experimental Models

The available literature spans immortalized BV2 cells, primary rodent microglia, human induced pluripotent stem cell-derived microglia, peripheral macrophages, transgenic amyloid and tau models, and non-AD inflammatory paradigms. Each system captures selected biological processes and omits others. BV2 cells are useful for rapid screening, but their metabolic characteristics and inflammatory responses differ from those of human adult microglia. Human stem-cell-derived systems retain human genetic contexts while often lacking the maturation and multicellular environmental cues of aged human brain tissue. Animal AD models permit behaviour and brain pathology measurement but cannot reproduce every feature of sporadic late-onset disease.

A staged experimental pipeline is preferable to assuming that one model supplies all needed evidence. Initial screening can establish nontoxic congener concentrations and broad immune effects; primary and donor-derived systems can test reproducibility and genotype interactions; cocultures can determine whether microglial changes influence neuronal survival or synapses; and animal experiments can relate verified exposure to amyloid, tau and cognition. Negative findings at any stage should refine or terminate the hypothesis rather than merely prompt a switch to more favorable outcome measures. A strong research program should specify stop criteria and primary endpoints in advance.

Pharmacokinetic Realism and Congener-Specific Exposure

Bioavailability remains one of the central bottlenecks. Oral tocotrienol exposure varies across preparations, and a formulation that increases plasma levels may change the balance of congeners reaching different organs. Nanoencapsulation studies show that distribution can be altered, including tissue-specific and congener-specific effects. This means dose comparisons expressed simply in milligrams of total tocotrienols are insufficient to interpret biological equivalence. The relevant quantities include molecular identity, dose-normalized systemic exposure, unbound concentration where feasible, metabolic products, and time

course. In vivo brain measurements must control for vascular contamination and distinguish tissue deposition from functionally available intracellular compound.

A particularly important inference concerns garcinoic acid and other downstream metabolites. Their cellular activities should not be used to claim that an orally administered palm tocotrienol preparation will reproduce the same effects. Demonstrating a metabolic pathway is not the same as quantifying metabolite generation, transport or persistence in a disease-relevant tissue. Future studies should use validated chromatographic and mass-spectrometric assays for parent congeners and relevant metabolites, preferably linked to pharmacodynamic measurements in the same subjects or animals. Without those data, a mechanistically sophisticated pathway diagram may remain pharmacologically disconnected from achievable human exposure.

Integrating Biomarker and Functional Outcomes

Alzheimer's biomarkers now support much more specific definition of study populations than clinical symptoms alone. Amyloid and tau measures can establish biological disease status, while additional indices such as glial proteins, neurofilament light and inflammatory imaging may characterize associated cellular responses. For a tocotrienol study, however, the key question is not whether one marker shifts but whether the shift is attributable to the intervention, biologically coherent and related to a prespecified outcome. A reduction in GFAP may reflect altered astrocytic responses without showing direct microglial NLRP3 engagement, while TSPO PET signals are not molecularly specific for the inflammasome.

The revised biological criteria for Alzheimer's disease distinguish core amyloid and tau biomarkers, which inform the presence and stage of AD pathology, from markers of less disease-specific processes such as neuronal injury and glial activation. This hierarchy matters for trials of putative immunometabolic interventions: amyloid or tau markers can anchor disease classification, while inflammatory and glial measurements require separate analytical validation for their proposed pharmacodynamic roles. Neither changes in plasma GFAP nor alterations in peripheral IL-1β can independently establish target engagement within brain microglia, and no biomarker substitution should displace cognitive, functional and safety assessment when clinical efficacy is being tested. A prespecified endpoint hierarchy would therefore reduce the risk of interpreting exploratory glial changes as demonstrated disease modification.

Clinical cognition also requires careful interpretation. Laboratory tasks measuring exploration or recognition in rodents should not be presented as equivalents of validated human memory or daily-function scales. In a trial of an investigational adjunct, preclinical cognitive outcomes should be supported by disease biomarker changes and relevant safety observations, while human studies must prespecify clinical endpoints and clinically important differences. Approved anti-amyloid trials provide an example of the methodological rigor necessary to relate pathological change to functional effects, without implying that tocotrienols are likely to achieve comparable treatment effects.

Evidence Matrix and Classification of Certainty

The evidence can be organized into three substantive levels of confidence. The strongest AD-specific mechanistic evidence establishes that microglial metabolism, lipid handling and NLRP3 signalling interact in controlled research systems. A more limited but still substantive experimental literature shows tocotrienol-associated changes in selected immune and neuronal pathways outside disease-definitive human AD settings. The weakest link is the proposed connection between defined palm-derived congeners, verified brain target engagement and clinical Alzheimer's benefit. Treating these levels as equivalent would produce an inflated therapeutic narrative. The value of the review is to make the missing connections visible and experimentally tractable.

There are also nontrivial negative and boundary observations. Some experimental inflammatory markers do not respond consistently to tocotrienol preparations, and mixed fractions obstruct congener attribution. The neutral CADASIL trial cautions against assuming that long-standing neuroprotective hypotheses necessarily yield human benefit. Meanwhile, microglial activation itself can have contradictory effects depending on disease stage and the measurement used. Accordingly, the most defensible conclusion is not that tocotrienols have failed or succeeded as AD interventions, but that evidence remains insufficient to adjudicate the disease-specific clinical hypothesis.

Proposed Experimental and Translational Agenda

A first experimental phase should compare purified palm-derived α-, γ- and δ-tocotrienols with chemically characterized tocotrienol-rich fractions and matched controls. Studies should assess vehicle effects, dose-dependent viability, and the stability of parent compounds and metabolites in culture media. The same experiments should measure both NLRP3-specific endpoints and mitochondrial, glycolytic and phagocytic functions. Use of a selective NLRP3 inhibitor and genetic loss-of-function control would help determine whether the proposed mechanism is NLRP3-dependent. This foundational phase should be completed before expanding into expensive cognitive or therapeutic trials.

A second phase should use disease-relevant human microglial systems under standardized amyloid and tau challenge. Isogenic APOE and TREM2 backgrounds, independent donors and defined cocultures with neurons and astrocytes would allow exploration of genotype-dependent and non-cell-autonomous effects. Experiments should also evaluate whether inflammatory suppression coincides with improved clearance and neuronal health rather than diminished immune capacity. Multi-omic observations could be useful for hypothesis generation, but critical mechanisms must be confirmed by perturbation and functional measures. This is especially important because microglial states can reflect response to pathology rather than a causal driver of progression.

A third phase should establish animal and, if feasible, human pharmacokinetic exposure before efficacy testing. Candidate formulations would be advanced only when brain or appropriate CNS-associated exposure measurements plausibly cover the active in vitro concentration range without safety concerns. Biomarker-confirmed AD populations should be considered only after replicated evidence of functional target engagement, followed by carefully designed early-phase safety and mechanism studies. Any eventual efficacy trial would need appropriate randomisation, blinding, adequate duration and clinical outcome measures. Because the compound class already has a heterogeneous clinical evidence base, explicit go/no-go criteria would improve scientific efficiency and ethical resource allocation [31-49].

Figure 3 translates these experimental requirements into a staged research agenda with explicit decision gates separating chemical

characterisation, molecular causality, microglial functional integrity, realistic central exposure, disease-model validity, and eventual human investigation. The sequence is deliberately conditional: failure to establish a prior gate should trigger reformulation or termination rather than automatic advancement.




Figure 3: Translational Stages and Stop/Go Evidence Requirements

Figure 3 outlines a stepwise translational decision pathway in which each transition requires evidence rather than enthusiasm about a biological hypothesis. Compound analytics, mechanistic causality, exposure verification and functional protection are positioned before trials involving patients. The model discourages premature advancement based on antioxidant assays or animal behaviour alone and provides a transparent structure for future grant proposals and multidisciplinary collaboration.

Broader Implications for Responsible Palm-Bioactive Innovation

Palm-derived bioactive research occupies an unusual intersection between agricultural processing, nutritional science, industrial biotechnology and clinical medicine. This intersection creates opportunities for compound isolation, fraction standardization and pharmaceutical formulation, but it also generates risks of conflating commercial source advantages with therapeutic effectiveness. A palm-based extraction route may be scalable and valuable even when the resulting ingredient proves unsuitable for an Alzheimer's intervention. Research programs should therefore assess compound identity, sustainable supply, production reproducibility and biological validity as separate questions. A clinically unproven mechanism should not be used to market treatment claims for vulnerable people with dementia.

From a scholarly perspective, the review also highlights the need for methodological integration. Neuroscientists can specify disease-relevant cell states and outcome measures, analytical chemists can establish exposure and purity, and pharmacologists can determine whether target engagement is plausible. Translational researchers can then design studies that avoid substituting peripheral biomarkers for central mechanisms or short-term rodent behaviour for human clinical function. Multidisciplinary collaboration is most valuable when it exposes weak links rather than simply accumulating favorable observations. The proposed framework can therefore contribute to wider natural-product research by treating negative evidence, mechanistic uncertainty and dose realism as productive scientific findings [50-69].

Conclusion

The contemporary literature positions microglial immunometabolism and NLRP3-associated signalling as important, dynamically connected components of Alzheimer's disease biology. Microglia must balance inflammatory responses with metabolic adaptation, lipid processing, amyloid interaction and tissue maintenance, and these functions vary across disease stages and genetic contexts. Palm-derived tocotrienols have demonstrated selected anti-inflammatory and neuroprotective signals in experimental systems, while related vitamin E metabolites offer additional mechanistic leads. Nevertheless, no adequate body of clinical evidence currently demonstrates that defined palm tocotrienol congeners directly modulate NLRP3 in the human Alzheimer's brain or improve cognitive outcomes through that mechanism.

The principal scientific contribution of this review is an evidence-calibrated, congener-to-exposure-to-function framework that distinguishes mechanistic possibility from disease-specific proof. A reduction in ROS or inflammatory gene expression should not be interpreted as direct inflammasome inhibition, and an effect in peripheral macrophages or non-AD animals cannot be automatically extrapolated to patient benefit. Future research should combine chemically standardized compounds, dose-realistic brain pharmacology, causal perturbation of inflammasome pathways and simultaneous measurement of beneficial and harmful microglial functions. Disease-stage and genotype-sensitive experiments would provide a more informative foundation than unstratified assays of broad anti-inflammatory activity.

The most immediate recommendation is to prioritize rigorous human-cell and disease-relevant preclinical investigations before clinical efficacy trials. Prospective studies should prespecify target-engagement criteria, integrate metabolic and immune biomarkers, account for treatment timing, and include safety and functional outcomes. If pharmacological exposure or causal effects cannot be demonstrated, investigators should be prepared to abandon or redirect the hypothesis rather than generalize from weaker evidence. Such a strategy can generate meaningful scientific insight whether the eventual clinical results are favorable, neutral or negative.

Palm-derived tocotrienols should consequently be understood as investigational molecules with plausible but unconfirmed applications in Alzheimer's neuroimmune research. Their value to the field will depend less on the repetition of antioxidant claims than on the production of reproducible experiments that clarify causal mechanisms, appropriate exposure, protective microglial functions and clinically relevant outcomes. A restrained and falsifiable translational agenda offers the strongest basis for responsible innovation in this area.

References

1. Adamu A (2024) The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets. Frontiers in Aging Neuroscience 16: 1347987.
2. AmeliMojarad M, AmeliMojarad M (2024) The neuroinflammatory role of microglia in Alzheimer's disease and their associated therapeutic targets. CNS Neuroscience & Therapeutics 30: e14856.
3. Ang SY (2025) Modulation of NF-κB signaling pathway by tocotrienol in neurodegenerative diseases. Discover Mental Health 5: 160.
4. Ayyubova G, Madhu LN (2025) Microglial NLRP3 inflammasomes in Alzheimer's disease pathogenesis: from interaction with autophagy/mitophagy to therapeutics. Molecular Neurobiology 62: 7124–7143.
5. Bai H, Zhang Q (2021) Activation of NLRP3 inflammasome and onset of Alzheimer's disease. Frontiers in Immunology 12: 701282.
6. Baligács N (2024) Homeostatic microglia initially seed and activated microglia later reshape amyloid plaques in Alzheimer's disease. Nature Communications 15: 10634.
7. Bartolini D (2020) Garcinoic acid is a natural and selective agonist of pregnane X receptor. Journal of Medicinal Chemistry 63: 3701–3712.
8. Börmel L (2025) The vitamin E derivative garcinoic acid suppresses NLRP3 inflammasome activation and pyroptosis in murine macrophages. Inflammation 48: 3340–3352.
9. Chabriat H (2026) Tocotrienol-rich vitamin E complex in CADASIL (T3CAD): a randomised, double-blind, placebo-controlled trial. eClinicalMedicine 94: 103853.
10. Chen H (2024) Neuroinflammation of microglial regulation in Alzheimer's disease: therapeutic approaches. Molecules 29: 1478.
11. Chen W (2025) Loss of insulin signaling in microglia impairs cellular uptake of Aβ and neuroinflammatory response exacerbating AD-like neuropathology. Proceedings of the National Academy of Sciences 122: e2501527122.
12. Cheon J, Kwon S, Kim M (2025) Exerkines mitigating Alzheimer's disease progression by regulating inflammation: focusing on macrophage/microglial NLRP3 inflammasome pathway. Alzheimer's & Dementia 21: e14432.
13. Claes C (2021) Plaque-associated human microglia accumulate lipid droplets in a chimeric model of Alzheimer's disease. Molecular Neurodegeneration 16: 50.
14. D'Oliveira Albanus R (2025) Systematic analysis of cellular cross-talk reveals a role for SEMA6D–TREM2 regulating microglial function in Alzheimer's disease. Science Translational Medicine 17: eadx0027.
15. Ebrahimi R (2025) Microglial activation as a hallmark of neuroinflammation in Alzheimer's disease. Metabolic Brain Disease 40: 207.
16. Eshraghi M (2021) Alzheimer's disease pathogenesis: role of autophagy and mitophagy focusing in microglia. International Journal of Molecular Sciences 22: 3330.
17. Fu JY (2023) Effect of nano-delivery systems on the bioavailability and tissue biodistribution of vitamin E tocotrienols. Food Research International 171: 113048.
18. Gao R (2025) Decoding microglial polarization and metabolic reprogramming in neurodegenerative diseases: implications for disease progression and therapy. Aging and Disease 17: 91–113.
19. Geng F, Zhao N, Ren Q (2025) Circadian rhythm, microglia-mediated neuroinflammation, and Alzheimer's disease. Neuroscience & Biobehavioral Reviews 170: 106044.
20. Golzari-Sorkheh M (2021) The NLRP3 inflammasome in the pathogenesis and treatment of Alzheimer's disease. Journal of Alzheimer's Disease 84: 579–598.
21. Guan Y, Han F (2020) Key mechanisms and potential targets of the NLRP3 inflammasome in neurodegenerative diseases. Frontiers in Integrative Neuroscience 14: 37.
22. Guo M (2025) Ciliatoside A attenuates neuroinflammation in Alzheimer's disease by activating mitophagy and inhibiting NLRP3 inflammasome activation. Phytomedicine 156928.
23. Haney MS (2024) APOE4/4 is linked to damaging lipid droplets in Alzheimer's disease microglia. Nature 628: 154–161.
24. Hanslik KL, Ulland TK (2020) The role of microglia and the NLRP3 inflammasome in Alzheimer's disease. Frontiers in Neurology 11: 570711.
25. Heneka MT (2025) Neuroinflammation in Alzheimer disease. Nature Reviews Immunology 25: 321–352.
26. Huang H, Xiang R, Yan R (2024) Linking APOE4/4 genotype to microglial lipid droplets and neurotoxicity in Alzheimer's disease. Translational Neurodegeneration 13: 38.
27. Jack CR Jr (2024) Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimer's & Dementia 20: 5143–5169.
28. Jha D, Bakker ENTP, Kumar R (2024) Mechanistic and therapeutic role of NLRP3 inflammasome in the pathogenesis of Alzheimer's disease. Journal of Neurochemistry 168: 3574–3598.
29. Jung ES, Choi H, Mook-Jung I (2025) Decoding microglial immunometabolism: a new frontier in Alzheimer's disease research. Molecular Neurodegeneration 20: 37.
30. Kang X (2025) Microglia-neuron crosstalk in Alzheimer's disease: an exploration of molecular mechanisms and pathological implications. Neuroscience 583: 1–9.
31. Kwon HS, Koh SH (2020) Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Translational Neurodegeneration 9: 42.
32. Liang T (2022) The role of NLRP3 inflammasome in Alzheimer's disease and potential therapeutic targets. Frontiers in Pharmacology 13: 845185.
33. Looi AD (2025) Health benefits of palm tocotrienol-rich fraction: a systematic review of randomized controlled trials. Nutrition Reviews 83: 307–328.
34. Lu A (2026) Human microglial transitions at the Aβ–tau

inflection point associate with divergent pathways to dementia and resilience. Nature Medicine 32: 2047–2059.
35. Lu N (2025) Microglial glycolytic reprogramming in Alzheimer's disease: association with impaired phagocytic function and altered vascular proximity. Journal of Neuroinflammation 22: 223.
36. Mao M (2025) Microglial APOE4 promotes neuron degeneration in Alzheimer's disease through inhibition of lipid droplet autophagy. Acta Pharmaceutica Sinica B 15: 657–660.
37. Marschallinger J (2020) Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain. Nature Neuroscience 23: 194–208.
38. Martins-Ferreira R (2025) The Human Microglia Atlas (HuMicA) unravels changes in disease-associated microglia subsets across neurodegenerative conditions. Nature Communications 16: 739.
39. McManus RM (2025) NLRP3-mediated glutaminolysis controls microglial phagocytosis to promote Alzheimer's disease progression. Immunity 58: 326–343.e11.
40. Milner MT (2021) The NLRP3 inflammasome triggers sterile neuroinflammation and Alzheimer's disease. Current Opinion in Immunology 68: 116–124.
41. Mohamad NV (2023) Strategies to enhance the solubility and bioavailability of tocotrienols using self-emulsifying drug delivery system. Pharmaceuticals 16: 1403.
42. Nugent AA (2020) TREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge. Neuron 105: 837–854.e9.
43. Okuyama S (2021) Neuroprotective and anti-microglial activation effects of tocotrienols in brains of lipopolysaccharide-induced inflammatory model mice. Neuroglia 2: 9.
44. Palmqvist S (2025) Alzheimer's Association clinical practice guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings. Alzheimer's & Dementia 21: e70535.
45. Pan FF (2025) Plasma P-tau217, GFAP, and NfL as biomarkers for Alzheimer's disease: role in disease stratification, pathological progression, and cognitive decline. Alzheimer's & Dementia 21: e70987.
46. Permann S (2026) Tocotrienol metabolites redirect lipid mediator production in innate immune cells towards inflammation resolution. Acta Pharmaceutica Sinica B 16: 6099–6128.
47. Pilat DJ (2026) The gain-of-function TREM2–T96K mutation increases risk for Alzheimer's disease by impairing microglial function. Neuron 114: 46–66.e13.
48. Pola I (2025) Exploring inflammation-related protein expression and its relationship with TSPO PET in Alzheimer's disease. Alzheimer's & Dementia 21: e70171.
49. Prakash P (2025) Amyloid-β induces lipid droplet-mediated microglial dysfunction via the enzyme DGAT2 in Alzheimer's disease. Immunity 58: 1536–1552.e8.
50. Rachmian N (2024) Identification of senescent, TREM2-expressing microglia in aging and Alzheimer's disease model mouse brain. Nature Neuroscience 27: 1116–1124.
51. Rao C, Semrau S, Fossati V (2025) Decoding microglial functions in Alzheimer's disease: insights from human models. Trends in Immunology 46: 310–323.
52. Retinasamy T (2024) Repurposing anakinra for Alzheimer's disease: the in vitro and in vivo effects of anakinra on LPS- and AC-induced neuroinflammation. ACS Chemical Neuroscience 15: 3298–3310.
53. Rui J (2024) Tocotrienol-rich fraction enhances cell proliferation and memory formation in hippocampal HT22 neuronal cells through BDNF/TrkB pathway. Journal of Functional Foods 116: 106178.
54. Saha S (2020) An overview of Nrf2 signaling pathway and its role in inflammation. Molecules 25: 5474.
55. Sharif M (2023) Pharmacokinetics and bioavailability of tocotrienols in healthy human volunteers: a systematic review. Journal of Pakistan Medical Association 73: 603–610.
56. Sharma B (2023) Role of NLRP3 inflammasome and its inhibitors as emerging therapeutic drug candidate for Alzheimer's disease: a review of mechanism of activation, regulation, and inhibition. Inflammation 46: 56–87.
57. Sims JR (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330: 512–527.
58. Singh S, Singh TG (2020) Role of nuclear factor kappa B (NF-κB) signalling in neurodegenerative diseases: an mechanistic approach. Current Neuropharmacology 18: 918–935.
59. Subedi L (2021) Nitric oxide as a target for phytochemicals in anti-neuroinflammatory prevention therapy. International Journal of Molecular Sciences 22: 4771.
60. Tan JY (2026) Exploring the role of tocotrienol-rich fraction (TRF) in ameliorating neuroinflammation. Inflammopharmacology 34: 4117–4130.
61. van Dyck CH (2023) Lecanemab in early Alzheimer's disease. New England Journal of Medicine 388: 9–21.
62. van Lengerich B (2023) A TREM2-activating antibody with a blood–brain barrier transport vehicle enhances microglial metabolism in Alzheimer's disease models. Nature Neuroscience 26: 416–429.
63. van Olst L (2025) Microglial mechanisms drive amyloid-β clearance in immunized patients with Alzheimer's disease. Nature Medicine 31: 1604–1616.
64. Wallert M, Börmel L, Lorkowski S (2021) Inflammatory diseases and vitamin E—what do we know and where do we go? Molecular Nutrition & Food Research 65: e2000097.
65. Wang H (2025) H4K12 lactylation-regulated NLRP3 is involved in cigarette smoke-accelerated Alzheimer-like pathology through mTOR-regulated autophagy and activation of microglia. Journal of Hazardous Materials 488: 137310.
66. Yao J (2023) Targeting NLRP3 inflammasome for neurodegenerative disorders. Molecular Psychiatry 28: 4512–4527.
67. Zhang D (2023) Degradation of NLRP3 by p62-dependent-autophagy improves cognitive function in Alzheimer's disease by maintaining the phagocytic function of microglia. CNS Neuroscience & Therapeutics 29: 2826–2842.
68. Zhang Z (2024) Glutamine metabolism modulates microglial NLRP3 inflammasome activity through mitophagy in Alzheimer's disease. Journal of Neuroinflammation 21: 261.
69. Zou Y (2026) Microglial immunometabolism in Alzheimer's disease: a stage-resolved trajectory from adaptive remodeling to the metabolic paradox. Biomedicine & Pharmacotherapy 202: 119841.

Copyright: ©2026 Loso Judijanto. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.